161 related articles for article (PubMed ID: 9862270)
1. Effects of lipids and lipoproteins on thrombosis and rheology.
Rosenson RS; Lowe GD
Atherosclerosis; 1998 Oct; 140(2):271-80. PubMed ID: 9862270
[TBL] [Abstract][Full Text] [Related]
2. Lipoproteins and the haemostatic system in atherothrombotic disorders.
Miller GJ
Baillieres Clin Haematol; 1994 Sep; 7(3):713-32. PubMed ID: 7841607
[TBL] [Abstract][Full Text] [Related]
3. High-density lipoprotein from patients with coronary heart disease loses anti-thrombotic effects on endothelial cells: impact on arterial thrombus formation.
Holy EW; Besler C; Reiner MF; Camici GG; Manz J; Beer JH; Lüscher TF; Landmesser U; Tanner FC
Thromb Haemost; 2014 Nov; 112(5):1024-35. PubMed ID: 25056722
[TBL] [Abstract][Full Text] [Related]
4. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
5. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
6. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
Petersen KR
Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
[TBL] [Abstract][Full Text] [Related]
8. Impact of simvastatin on hemostatic and fibrinolytic regulators in Type 2 diabetes mellitus.
Ludwig S; Dharmalingam S; Erickson-Nesmith S; Ren S; Zhu F; Ma GM; Zhao R; Fenton JW; Ofosu FA; Velthuis HT; van Mierlo G; Shen GX
Diabetes Res Clin Pract; 2005 Nov; 70(2):110-8. PubMed ID: 16188573
[TBL] [Abstract][Full Text] [Related]
9. Lipid-thrombosis interface.
Mitropoulos KA
Br Med Bull; 1994 Oct; 50(4):813-32. PubMed ID: 7804733
[TBL] [Abstract][Full Text] [Related]
10. Imbalance of plasminogen activator inhibitor-I/ tissue plasminogen activator and tissue factor/tissue factor pathway inhibitor in young Japanese men with myocardial infarction.
Saigo M; Abe S; Ogawa M; Yamashita T; Biro S; Minagoe S; Maruyama I; Tei C
Thromb Haemost; 2001 Nov; 86(5):1197-203. PubMed ID: 11816707
[TBL] [Abstract][Full Text] [Related]
11. Effects of VLDL and remnant particles on platelets.
Olufadi R; Byrne CD
Pathophysiol Haemost Thromb; 2006; 35(3-4):281-91. PubMed ID: 16877877
[TBL] [Abstract][Full Text] [Related]
12. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells.
Markle RA; Han J; Summers BD; Yokoyama T; Hajjar KA; Hajjar DP; Gotto AM; Nicholson AC
J Cell Biochem; 2003 Sep; 90(1):23-32. PubMed ID: 12938153
[TBL] [Abstract][Full Text] [Related]
13. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study.
Meigs JB; Mittleman MA; Nathan DM; Tofler GH; Singer DE; Murphy-Sheehy PM; Lipinska I; D'Agostino RB; Wilson PW
JAMA; 2000 Jan; 283(2):221-8. PubMed ID: 10634338
[TBL] [Abstract][Full Text] [Related]
14. Serum triglycerides and blood coagulation factors VII and X, and plasminogen activator inhibitor-1.
Ohni M; Mishima K; Nakajima K; Yamamoto M; Hata Y
J Atheroscler Thromb; 1995; 2 Suppl 1():S41-6. PubMed ID: 9225231
[TBL] [Abstract][Full Text] [Related]
15. Association of the fibrinolytic system and hemorheology with symptoms in patients with carotid occlusive disease.
Soinne L; Saimanen E; Malmberg-Céder K; Kovanen P; Lindsberg PJ; Kaste M; Lassila R
Cerebrovasc Dis; 2005; 20(3):172-9. PubMed ID: 16088112
[TBL] [Abstract][Full Text] [Related]
16. Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein.
Siess W
Pathophysiol Haemost Thromb; 2006; 35(3-4):292-304. PubMed ID: 16877878
[TBL] [Abstract][Full Text] [Related]
17. Effects of lipids on thrombotic mechanisms in atherosclerosis.
Tousoulis D; Davies G; Ambrose J; Tentolouris C; Stefanadis C; Toutouzas P
Int J Cardiol; 2002 Dec; 86(2-3):239-47. PubMed ID: 12419562
[TBL] [Abstract][Full Text] [Related]
18. [Current views of activating and regulatory mechanisms of blood coagulation].
Osaki T; Ichinose A
Nihon Rinsho; 2014 Jul; 72(7):1206-11. PubMed ID: 25163309
[TBL] [Abstract][Full Text] [Related]
19. Clustering of cardiovascular risk factors: targeting high-risk individuals.
Genest J; Cohn JS
Am J Cardiol; 1995 Jul; 76(2):8A-20A. PubMed ID: 7604805
[TBL] [Abstract][Full Text] [Related]
20. Diabetes mellitus as a prothrombotic condition.
Grant PJ
J Intern Med; 2007 Aug; 262(2):157-72. PubMed ID: 17645584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
